000864751 001__ 864751
000864751 005__ 20210130002714.0
000864751 0247_ $$2doi$$a10.1186/s13550-019-0540-7
000864751 0247_ $$2Handle$$a2128/22687
000864751 0247_ $$2altmetric$$aaltmetric:64246633
000864751 0247_ $$2pmid$$apmid:31346821
000864751 0247_ $$2WOS$$aWOS:000477581200003
000864751 037__ $$aFZJ-2019-04418
000864751 082__ $$a610
000864751 1001_ $$00000-0002-8128-9058$$aHohberg, Melanie$$b0$$eCorresponding author
000864751 245__ $$aBiodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer
000864751 260__ $$aHeidelberg$$bSpringer$$c2019
000864751 3367_ $$2DRIVER$$aarticle
000864751 3367_ $$2DataCite$$aOutput Types/Journal article
000864751 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1568013678_22203
000864751 3367_ $$2BibTeX$$aARTICLE
000864751 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000864751 3367_ $$00$$2EndNote$$aJournal Article
000864751 520__ $$aAim We investigated the whole-body distribution and the radiation dosimetry of [18F]-JK-PSMA-7, a novel 18F-labeled PSMA-ligand for PET/CT imaging of prostate cancer.MethodsTen patients with prostate cancer and biochemical recurrence or radiologic evidence of metastatic diseases were examined with 329–384 MBq (mean 359 ± 17 MBq) [18F]-JK-PSMA-7. Eight sequential positron emission tomography (PET) scans were acquired from 20 min to 3 h after injection with IRB approval. The kidneys, liver, lungs, spleen, and salivary glands were segmented into volumes of interest using the QDOSE dosimetry software suite (ABX-CRO, Germany). Absorbed and effective dose were calculated using the ICRP-endorsed IDAC 1.0 package. The absorbed dose of the salivary glands was determined using the spherical model of OLINDA 1.1. PSMA-positive lesions were evaluated separately. Quantitative assessment of the uptake in suspicious lesions was performed by analysis of maximum (max) and peak SUV values. The gluteus maximus muscle (SUVmean) served as a reference region for the calculation of tumor-to-background ratios (TBR’s).ResultsPhysiologic radiotracer accumulation was observed in the salivary and lacrimal glands, liver, spleen, and intestines, in a pattern resembling the distribution known from other PSMA-tracers with excretion via urinary and biliary pathways. The effective dose from [18F]-JK-PSMA-7 for the whole body was calculated to be 1.09E−02 mGy/MBq. The highest radiation dose was observed in the kidneys (1.76E−01 mGy/MBq), followed by liver (7.61E−02 mGy/MBq), salivary glands (4.68E−02 mGy/MBq), spleen (1.89E−02 mGy/MBq), and lungs (1.10E-2 mGy/MBq). No adverse effects of tracer injection were observed. Six out of ten patients were scored as PSMA-positive. A total of 18 suspicious lesions were analyzed, which included six bone lesions, nine lymph nodes, and three local lesions within the prostate fossa. The values for the SUVmax and SUVpeak in the PSMA-positive lesions increased until 60 min p.i. and remained at this intensity in the PET/CT scans until 140 min. In the period between 170 and 200 min after injection, a further significant increase in SUVmax and SUVpeak within the PSMA-positive lesions was observed.ConclusionsThe highest TBR of [18F]-JK-PSMA-7 was found 3 h after injection. From the kinetically collected data, it can be concluded that this trend may also continue in the further course. The start of the PET/CT acquisition should be chosen as late as possible. The high uptake in suspicious lesions in terms of absolute SUVmax and relative TBR values indicates potentially high sensitivity of the tracer for detection of prostate cancer manifestations.
000864751 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000864751 588__ $$aDataset connected to CrossRef
000864751 7001_ $$0P:(DE-HGF)0$$aKobe, Carsten$$b1
000864751 7001_ $$0P:(DE-Juel1)169356$$aKrapf, Philipp$$b2$$ufzj
000864751 7001_ $$0P:(DE-HGF)0$$aTäger, Philipp$$b3
000864751 7001_ $$0P:(DE-HGF)0$$aHammes, Jochen$$b4
000864751 7001_ $$0P:(DE-HGF)0$$aDietlein, Felix$$b5
000864751 7001_ $$0P:(DE-Juel1)176188$$aZlatopolskiy, Boris D.$$b6$$ufzj
000864751 7001_ $$0P:(DE-HGF)0$$aEndepols, Heike$$b7
000864751 7001_ $$0P:(DE-HGF)0$$aWild, Markus$$b8
000864751 7001_ $$0P:(DE-HGF)0$$aNeubauer, Stephan$$b9
000864751 7001_ $$0P:(DE-HGF)0$$aHeidenreich, Axel$$b10
000864751 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b11$$ufzj
000864751 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b12$$ufzj
000864751 7001_ $$0P:(DE-HGF)0$$aDietlein, Markus$$b13
000864751 773__ $$0PERI:(DE-600)2619892-7$$a10.1186/s13550-019-0540-7$$gVol. 9, no. 1, p. 66$$n1$$p66$$tEJNMMI Research$$v9$$x2191-219X$$y2019
000864751 8564_ $$uhttps://juser.fz-juelich.de/record/864751/files/Hohberg2019_Article_BiodistributionAndRadiationDos.pdf$$yOpenAccess
000864751 8564_ $$uhttps://juser.fz-juelich.de/record/864751/files/Hohberg2019_Article_BiodistributionAndRadiationDos.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000864751 909CO $$ooai:juser.fz-juelich.de:864751$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000864751 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)169356$$aForschungszentrum Jülich$$b2$$kFZJ
000864751 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)176188$$aForschungszentrum Jülich$$b6$$kFZJ
000864751 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b11$$kFZJ
000864751 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b12$$kFZJ
000864751 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000864751 9141_ $$y2019
000864751 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000864751 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000864751 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000864751 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEJNMMI RES : 2017
000864751 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000864751 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000864751 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000864751 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000864751 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000864751 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000864751 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000864751 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000864751 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000864751 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000864751 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000864751 920__ $$lyes
000864751 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000864751 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x1
000864751 980__ $$ajournal
000864751 980__ $$aVDB
000864751 980__ $$aUNRESTRICTED
000864751 980__ $$aI:(DE-Juel1)INM-5-20090406
000864751 980__ $$aI:(DE-Juel1)INM-2-20090406
000864751 9801_ $$aFullTexts